Please use this identifier to cite or link to this item: http://hdl.handle.net/11434/2100
Title: Tumor immune microenvironment of primary prostate cancer with and without germline mutations in homologous recombination repair genes.
Epworth Authors: Moon, Daniel
Murphy, Declan
Lawrentschuk, Nathan
Bolton, Damian
Other Authors: Trigos, Anna
Pasam, Anupama
Banks, Patricia
Wallace, Roslyn
Guo, Christina
Keam, Simon
Thorne, Heather
kConFab, Catherine
Lade, Stephen
Clouston, David
Hakansson, Alexander
Liu, Yang
Blyth, Benjamin
Darcy, Phil
Haupt, Ygal
Williams, Scott
Castro, Elena
Olmos, David
Goode, David
Neeson, Paul
Shahneen, Sandhu
Keywords: Gene Expression Profiling
Genetic Markers
Prostatic Neoplasms
Prostate Cancer
Tumor Microenvironment
Homologous Recombination Repair
HRR
Homologous Recombination Repair Deficiency
HRD
Tumor Immune Microenvironment
TIME
Poly ADP-Ribose Polymerase
PARP
Germline
Cancer Services Clinical Institute, Epworth HealthCare, Victoria, Australia
Epworth Prostate Centre, Epworth HealthCare, Victoria, Australia
Issue Date: Jun-2022
Publisher: BMJ
Citation: J Immunother Cancer . 2022 Jun;10(6):e003744
Abstract: Background: Aberrations in homologous recombination repair (HRR) genes are emerging as important biomarkers for personalized treatment in prostate cancer (PCa). HRR deficiency (HRD) could affect the tumor immune microenvironment (TIME), potentially contributing to differential responses to poly ADP-ribose polymerase (PARP) inhibitors and immune checkpoint inhibitors. Spatial distribution of immune cells in a range of cancers identifies novel disease subtypes and is related to prognosis. In this study we aimed to determine the differences in the TIME of PCa with and without germline (g) HRR mutations. Methods: We performed gene expression analysis, multiplex immunohistochemistry of T and B cells and quantitative spatial analysis of PCa samples from 36 patients with gHRD and 26 patients with sporadic PCa. Samples were archival tumor tissue from radical prostatectomies with the exception of one biopsy. Results were validated in several independent cohorts. Results: Although the composition of the T cell and B cells was similar in the tumor areas of gHRD-mutated and sporadic tumors, the spatial profiles differed between these cohorts. We describe two T-cell spatial profiles across primary PCa, a clustered immune spatial (CIS) profile characterized by dense clusters of CD4+ T cells closely interacting with PD-L1+ cells, and a free immune spatial (FIS) profile of CD8+ cells in close proximity to tumor cells. gHRD tumors had a more T-cell inflamed microenvironment than sporadic tumors. The CIS profile was mainly observed in sporadic tumors, whereas a FIS profile was enriched in gHRD tumors. A FIS profile was associated with lower Gleason scores, smaller tumors and longer time to biochemical recurrence and metastasis. Conclusions: gHRD-mutated tumors have a distinct immune microenvironment compared with sporadic tumors. Spatial profiling of T-cells provides additional information beyond T-cell density and is associated with time to biochemical recurrence, time to metastasis, tumor size and Gleason scores.
URI: http://hdl.handle.net/11434/2100
DOI: 10.1136/jitc-2021-003744
PubMed URL: https://pubmed.ncbi.nlm.nih.gov/35764368/
ISSN: 2051-1426
Journal Title: Journal of ImmunoTherapy of Cancer
Type: Journal Article
Affiliated Organisations: Division of Cancer Research, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.
Institute of Cancer Research Sutton, Sutton, Surrey, UK.
Royal Marsden Hospital Sutton, Sutton, London, UK.
Department of Pathology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
TissuPath, Melbourne, Victoria, Australia.
Veracyte Inc, South San Francisco, California, USA
Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Austin Hospital, Heidelberg, Victoria, Australia.
Division of Radiation Oncology and Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
Instituto de Investigacion Biomedica de Malaga, Malaga, Spain
Medical Oncology Department, Instituto de Investigación Hospital 12 de Octubre, Madrid, Spain.
Division of Cancer Research, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
Type of Clinical Study or Trial: Retrospective studies
Appears in Collections:Cancer Services
Epworth Prostate Centre

Files in This Item:
File Description SizeFormat  
moon.pdf7.85 MBAdobe PDFThumbnail
View/Open


Items in Epworth are protected by copyright, with all rights reserved, unless otherwise indicated.